Crispr, Vertex shares fall after FDA halts sickle-cell disease trialMarketWatchCrispr Therapeutics CRSP, +6.79% and Vertex Pharmaceuticals Inc. VRTX, +0.90% said late Wednesday the U.S. Food and Drug Administration has put a hold on a new-drug applicat… Continue reading
Harvard Medical School |
A Challenge Fit for CRISPR
Harvard Medical School “It’s relatively feasible to change one gene in a pig, but to change many dozens—which it’s quite clear is the minimum here—benefits from CRISPR,” Church said. Xenotransplantation is “one of few” big challenges (among them, gene drives and de … |
Fred Hutch News Service |
Nanoparticles take immunotherapy in new direction
Fred Hutch News Service Dr. Fan Zhang, a postdoctoral fellow in the laboratory of Dr. Matthias Stephan in Fred Hutchinson Cancer Research Center’s Clinical Research Division, is using nanoparticles to take immunotherapy in a new direction. The American Brain Tumor Association … |
The Scientist |
First Stem Cell Transplant In Utero Successful
The Scientist Pediatric surgeons at the University of California, San Francisco, have treated a second-trimester fetus with stem cells taken from her mother’s bone marrow. It is the first time a stem cell transplant has been successfully given to a patient in utero … |
The Scientist |
First Stem Cell Transplant In Utero Successful
The Scientist Pediatric surgeons at the University of California, San Francisco, have treated a second-trimester fetus with stem cells taken from her mother’s bone marrow. It is the first time a stem cell transplant has been successfully given to a patient in utero … |
Science Daily |
CLL patient goes into remission thanks to single CAR T cell
Science Daily Researchers at the University of Pennsylvania’s Abramson Cancer Center say a patient treated for chronic lymphocytic leukemia (CLL) in 2013 went into remission because of a single CAR T cell and the cells it produced as it multiplied, and has stayed … A single cell spurs 5-year remission for Penn leukemia patientPhillyVoice.com |